RELMADA THERAPEUTICS, INC. - 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Relmada Therapeutics, Inc. on December 14, 2015. The report covers a specific corporate event occurring on the same date regarding a change in the company's advisory leadership.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event notification and does not contain financial statements or performance metrics.
Material Changes
The primary material change reported is the appointment of James Dolan as an advisory partner. Mr. Dolan previously served as Senior Vice President of Licensing and Business Development at Purdue Pharma L.P.
Outlook and Management Commentary
Management commentary is limited to the announcement of the new advisory partnership. The filing references a press release (Exhibit 99.1) for further details but does not include specific guidance, risk factors, or contingencies within the body of this text.
Key Facts for Investor Verification
- James Dolan joined Relmada Therapeutics, Inc. as an advisory partner on December 14, 2015.
- Mr. Dolan brings prior experience from Purdue Pharma L.P. in licensing and business development.
- Review the attached press release (Exhibit 99.1) for the full scope of the advisory agreement.
- No financial data or operational results are disclosed in this specific filing.